The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy
Top Cited Papers
- 1 June 2007
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (11) , 3109-3114
- https://doi.org/10.1158/1078-0432.ccr-06-2798
Abstract
The immunosuppressive drug rapamycin played a key role in the functional characterization of mammalian target of rapamycin (mTOR), an unusual protein kinase that coordinates growth factor and nutrient availability with cell growth and proliferation. Several rapamycin-related compounds are now in various stages of clinical development as anticancer agents. This article highlights recent advances in our understanding of the mTOR signaling pathway and the implications of these findings for the clinical application of mTOR inhibitors in cancer patients.Keywords
This publication has 72 references indexed in Scilit:
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- Current development of mTOR inhibitors as anticancer agentsNature Reviews Drug Discovery, 2006
- AMP‐activated protein kinase – development of the energy sensor conceptThe Journal of Physiology, 2006
- Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancerNature Medicine, 2005
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiformeInvestigational New Drugs, 2005
- Antitumor Activity of Rapamycin in a Transgenic Mouse Model of ErbB2-Dependent Human Breast CancerCancer Research, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitiveNature Cell Biology, 2004
- TOR signalling in bugs, brain and brawnNature Reviews Molecular Cell Biology, 2003